Scholar Rock/$SRRK
1D1W1MYTD1Y5YMAX
Capital at risk
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Ticker
- $SRRK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 289
- Headquarters
- Cambridge, United States
- Website
- www.scholarrock.com
Scholar Rock Metrics
BasicAdvanced
$5.7B
-
-$3.36
0.67
-
Price and volume
Market cap
$5.7B
Beta
0.67
52-week high
$61.76
52-week low
$27.07
Average daily volume
1.6M
Financial strength
Current ratio
7.021
Quick ratio
6.812
Long term debt to equity
0.778
Total debt to equity
0.778
Interest coverage (TTM)
-29.63%
Profitability
EBITDA (TTM)
-404.883
Management effectiveness
Return on assets (TTM)
-58.82%
Return on equity (TTM)
-167.77%
Valuation
Price to book
22.35
Price to tangible book (TTM)
22.35
Price to free cash flow (TTM)
-19.099
Free cash flow yield (TTM)
-5.24%
Free cash flow per share (TTM)
-2.443
Growth
Earnings per share change (TTM)
2.18%
3-year earnings per share growth (CAGR)
5.05%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Analyst projections of the future price of Scholar Rock stock.
Bulls say / Bears say
The FDA approved ISEMBYLD as the first muscle-targeted treatment for SMA. In the SAPPHIRE trial, it improved HFMSE scores by 2.2 points versus background treatment alone, and 34.2% of treated patients gained at least three points versus 13.5% on placebo. (Business Wire)
The approval covers children aged two and above as well as adults, and Scholar Rock says ISEMBYLD can ship within days. Its patient-support programme is designed to help with insurance, financial assistance and infusion logistics, which could speed early commercial uptake. (Scholar Rock)
The FDA approval includes post-marketing obligations that management initially misstated on its investor call. Scholar Rock must run a pregnancy safety study and submit serious and non-serious fracture cases as 15-day alert reports, creating an ongoing safety and execution overhang. (StockTitan)
Commercial access may be slow because ISEMBYLD is a monthly intravenous add-on to existing SMA treatment. Management warned that, without an established J-code, the average time from prescription to infusion could exceed 60 days during the first six months. (The Motley Fool, TS2)
Scholar Rock remains heavily loss-making as it funds the launch and pipeline. It reported a $109.9 million second-quarter net loss and held $492.1 million in cash, equivalents and marketable securities at 30 June, so weak early sales could bring financing pressure back into focus. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Upcoming events
No upcoming events
Scholar Rock News
AllArticlesVideos
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Benzinga5 days ago
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Reuters5 days ago
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga5 days ago
Funds containing Scholar Rock
AllUSDGBPEUR
Fund name | Fund size | $SRRK weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.39% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.39% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.18% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.